A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Alirocumab in Chinese Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Sanofi
- 16 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Jan 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2018.
- 06 Dec 2016 New trial record